Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction

A one-year, prospective, randomized study

Hiroo Kumagai, Koichi Hayashi, Hiroya Kumamaru, Takao Saruta

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Unlike angiotensin converting enzyme inhibitors (ACEI), few long-term studies have shown calcium antagonists to retard the progression of renal dysfunction. Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension. A total of 72 hypertensive patients with serum creatinine (Cr) > 1.5 mg/dL were randomly allocated to treatment with either drug. During a 1-year period, 33% of the patients treated with ACEI dropped out due to adverse events, whereas 9% of patients with amlodipine dropped out. Data of 28 patients were available for analysis of more than 1-year follow-up. Reductions in blood pressure were comparable between the amlodipine (from 165/101 to 138/81 mm Hg) and ACEI groups. Serum Cr increased from 2.1 ± 0.8 (SD) to 2.6 ± 1.0 mg/dL with amlodipine (n = 16), but the difference was equivalent to that with ACEI (n = 12). Creatinine clearance (Ccr) in the moderate dysfunction group (basal Cr, 1.5 to 2.0 mg/dL) changed from 36 ± 10 to 33 ± 11 mL/min (not significant) with amlodipine, and the change was similar to that noted with ACEI. Annual declines in Ccr with amlodipine (-3.7 mL/min/year) and ACEI (-2.6 mL/min/year) were comparable, and both tended to be smaller than the annual decline in glomerular filtration rate reported in the Modification of Diet in Renal Disease study (-6 mL/min/year). Serum potassium was increased significantly (P < .01), from 4.5 ± 0.4 to 5.3 ± 0.8 mEq/L, only in the ACEI group. This 1-year prospective study demonstrated the effect of amlodipine on renal function to be likely the same as that of ACEI. Furthermore, amlodipine was better tolerated than ACEI for hypertensive patients with renal dysfunction. (C) 2000 American Journal of Hypertension, Ltd.

Original languageEnglish
Pages (from-to)980-985
Number of pages6
JournalAmerican Journal of Hypertension
Volume13
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Amlodipine
Angiotensin-Converting Enzyme Inhibitors
Prospective Studies
Kidney
Creatinine
Serum
Diet Therapy
Enalapril
Glomerulonephritis
Glomerular Filtration Rate
Potassium
Blood Pressure
Calcium

Keywords

  • ACE inhibitor
  • Adverse events
  • Amlodipine
  • Renoprotection
  • Serum potassium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction : A one-year, prospective, randomized study. / Kumagai, Hiroo; Hayashi, Koichi; Kumamaru, Hiroya; Saruta, Takao.

In: American Journal of Hypertension, Vol. 13, No. 9, 2000, p. 980-985.

Research output: Contribution to journalArticle

@article{739a3ce4db1c4ba2a828aa267a9f24ee,
title = "Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: A one-year, prospective, randomized study",
abstract = "Unlike angiotensin converting enzyme inhibitors (ACEI), few long-term studies have shown calcium antagonists to retard the progression of renal dysfunction. Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension. A total of 72 hypertensive patients with serum creatinine (Cr) > 1.5 mg/dL were randomly allocated to treatment with either drug. During a 1-year period, 33{\%} of the patients treated with ACEI dropped out due to adverse events, whereas 9{\%} of patients with amlodipine dropped out. Data of 28 patients were available for analysis of more than 1-year follow-up. Reductions in blood pressure were comparable between the amlodipine (from 165/101 to 138/81 mm Hg) and ACEI groups. Serum Cr increased from 2.1 ± 0.8 (SD) to 2.6 ± 1.0 mg/dL with amlodipine (n = 16), but the difference was equivalent to that with ACEI (n = 12). Creatinine clearance (Ccr) in the moderate dysfunction group (basal Cr, 1.5 to 2.0 mg/dL) changed from 36 ± 10 to 33 ± 11 mL/min (not significant) with amlodipine, and the change was similar to that noted with ACEI. Annual declines in Ccr with amlodipine (-3.7 mL/min/year) and ACEI (-2.6 mL/min/year) were comparable, and both tended to be smaller than the annual decline in glomerular filtration rate reported in the Modification of Diet in Renal Disease study (-6 mL/min/year). Serum potassium was increased significantly (P < .01), from 4.5 ± 0.4 to 5.3 ± 0.8 mEq/L, only in the ACEI group. This 1-year prospective study demonstrated the effect of amlodipine on renal function to be likely the same as that of ACEI. Furthermore, amlodipine was better tolerated than ACEI for hypertensive patients with renal dysfunction. (C) 2000 American Journal of Hypertension, Ltd.",
keywords = "ACE inhibitor, Adverse events, Amlodipine, Renoprotection, Serum potassium",
author = "Hiroo Kumagai and Koichi Hayashi and Hiroya Kumamaru and Takao Saruta",
year = "2000",
doi = "10.1016/S0895-7061(00)00287-9",
language = "English",
volume = "13",
pages = "980--985",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction

T2 - A one-year, prospective, randomized study

AU - Kumagai, Hiroo

AU - Hayashi, Koichi

AU - Kumamaru, Hiroya

AU - Saruta, Takao

PY - 2000

Y1 - 2000

N2 - Unlike angiotensin converting enzyme inhibitors (ACEI), few long-term studies have shown calcium antagonists to retard the progression of renal dysfunction. Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension. A total of 72 hypertensive patients with serum creatinine (Cr) > 1.5 mg/dL were randomly allocated to treatment with either drug. During a 1-year period, 33% of the patients treated with ACEI dropped out due to adverse events, whereas 9% of patients with amlodipine dropped out. Data of 28 patients were available for analysis of more than 1-year follow-up. Reductions in blood pressure were comparable between the amlodipine (from 165/101 to 138/81 mm Hg) and ACEI groups. Serum Cr increased from 2.1 ± 0.8 (SD) to 2.6 ± 1.0 mg/dL with amlodipine (n = 16), but the difference was equivalent to that with ACEI (n = 12). Creatinine clearance (Ccr) in the moderate dysfunction group (basal Cr, 1.5 to 2.0 mg/dL) changed from 36 ± 10 to 33 ± 11 mL/min (not significant) with amlodipine, and the change was similar to that noted with ACEI. Annual declines in Ccr with amlodipine (-3.7 mL/min/year) and ACEI (-2.6 mL/min/year) were comparable, and both tended to be smaller than the annual decline in glomerular filtration rate reported in the Modification of Diet in Renal Disease study (-6 mL/min/year). Serum potassium was increased significantly (P < .01), from 4.5 ± 0.4 to 5.3 ± 0.8 mEq/L, only in the ACEI group. This 1-year prospective study demonstrated the effect of amlodipine on renal function to be likely the same as that of ACEI. Furthermore, amlodipine was better tolerated than ACEI for hypertensive patients with renal dysfunction. (C) 2000 American Journal of Hypertension, Ltd.

AB - Unlike angiotensin converting enzyme inhibitors (ACEI), few long-term studies have shown calcium antagonists to retard the progression of renal dysfunction. Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension. A total of 72 hypertensive patients with serum creatinine (Cr) > 1.5 mg/dL were randomly allocated to treatment with either drug. During a 1-year period, 33% of the patients treated with ACEI dropped out due to adverse events, whereas 9% of patients with amlodipine dropped out. Data of 28 patients were available for analysis of more than 1-year follow-up. Reductions in blood pressure were comparable between the amlodipine (from 165/101 to 138/81 mm Hg) and ACEI groups. Serum Cr increased from 2.1 ± 0.8 (SD) to 2.6 ± 1.0 mg/dL with amlodipine (n = 16), but the difference was equivalent to that with ACEI (n = 12). Creatinine clearance (Ccr) in the moderate dysfunction group (basal Cr, 1.5 to 2.0 mg/dL) changed from 36 ± 10 to 33 ± 11 mL/min (not significant) with amlodipine, and the change was similar to that noted with ACEI. Annual declines in Ccr with amlodipine (-3.7 mL/min/year) and ACEI (-2.6 mL/min/year) were comparable, and both tended to be smaller than the annual decline in glomerular filtration rate reported in the Modification of Diet in Renal Disease study (-6 mL/min/year). Serum potassium was increased significantly (P < .01), from 4.5 ± 0.4 to 5.3 ± 0.8 mEq/L, only in the ACEI group. This 1-year prospective study demonstrated the effect of amlodipine on renal function to be likely the same as that of ACEI. Furthermore, amlodipine was better tolerated than ACEI for hypertensive patients with renal dysfunction. (C) 2000 American Journal of Hypertension, Ltd.

KW - ACE inhibitor

KW - Adverse events

KW - Amlodipine

KW - Renoprotection

KW - Serum potassium

UR - http://www.scopus.com/inward/record.url?scp=0033858105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033858105&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(00)00287-9

DO - 10.1016/S0895-7061(00)00287-9

M3 - Article

VL - 13

SP - 980

EP - 985

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 9

ER -